Latest News about BAYRY
Recent news which mentions BAYRY
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
From Benzinga
Menopause Management: Bayer's Non-Hormonal Treatment Option Shows Efficacy In Trial
January 08, 2024
From Benzinga
From Benzinga
Top Stocks, Sectors Loved By Congress Members Who Traded In 2023: Apple, NVIDIA, Microsoft, Ford And More Stocks To Watch In 2024
January 03, 2024
From Benzinga
Legal Victory For Bayer: Roundup Lawsuit Ends Five-Trial Losing Streak
December 26, 2023
From Benzinga
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
December 19, 2023
From Benzinga
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
From InvestorPlace
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
December 06, 2023
From Benzinga
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
December 04, 2023
From Benzinga
From Benzinga
3 Battered Blue-Chip Stocks to Sell in December
November 28, 2023
From InvestorPlace
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
November 24, 2023
From Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
November 20, 2023
From Benzinga
From Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
November 17, 2023
From Benzinga
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
November 08, 2023
From Benzinga
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
November 01, 2023
From Benzinga
Cathie Wood’s Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
September 27, 2023
From InvestorPlace
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
From Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
September 22, 2023
From Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
September 12, 2023
From Benzinga
From Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
August 28, 2023
From Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
August 21, 2023
From Benzinga
As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?
August 08, 2023
From Benzinga
Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema
July 31, 2023
From Benzinga
From Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
June 29, 2023
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.